Overview of Acard

Property	Description
Active ingredient	Acetylsalicylic acid (ASA)
Form	Enteric-coated tablets (Oral)
Pharmacological class	Platelet aggregation inhibitor (Antiplatelet agent)
Origin	Synthetic

What Type of Medicine is Acard?

Acard is a specific pharmaceutical preparation containing the active substance Acetylsalicylic acid (ASA). While this compound is chemically classified within the broad group of Nonsteroidal anti-inflammatory drugs (NSAIDs), Acard is primarily defined by its functional role as a Platelet aggregation inhibitor, or Antiplatelet agent. The compound itself is synthetic in origin and formulated in a low-dose regimen, a concentration clinically recognized for supporting long-term circulatory health. This targeted focus on blood modification distinguishes the preparation’s intent from that of higher-dose NSAID formulations typically used for managing acute pain or inflammation.

Composition and Enteric-Coated Form

Acard is a single active substance product manufactured as tablets for oral administration. Crucially, these are specialized enteric-coated tablets that possess a protective polymer layer. This unique feature is designed to resist dissolution by the highly acidic conditions of the stomach, minimizing direct gastric exposure to the Acetylsalicylic acid. The formulation ensures that the active ingredient is released only upon reaching the higher pH environment of the small intestine. This delayed, controlled release mechanism is primarily employed to help mitigate the potential for direct irritation to the gastric lining associated with the systemic use of ASA.

General Purpose of Acard

The fundamental purpose of Acard is to help maintain continuous and unobstructed blood circulation. It achieves this by selectively targeting and permanently modifying key enzymes within blood platelets. This modification results in the inhibition of platelet aggregation, meaning it reduces the ability of blood platelets to stick together and form unwanted clusters. The sustained effectiveness of this action establishes the medicine's role in providing a long-term, protective measure for maintaining healthy blood flow.

What side effects are possible with Acard?

Possible Side Effects and Safety Information

The safety profile of Acard (Acetylsalicylic acid, ASA) is defined by official government regulatory documents, which categorize possible effects by frequency and the body system affected. The primary safety concerns relate to the drug's antiplatelet action and its potential for systemic and gastrointestinal effects.

Officially documented adverse reactions are categorized primarily within the Gastrointestinal system and the Blood and Lymphatic System. Common effects listed in regulatory labeling often include dyspepsia (indigestion) and increased tendencies toward minor bleeding (e.g., gum bleeding or bruising). Less common reactions may involve skin manifestations like urticaria or rash.

Serious Adverse Reactions and Safety Constraints

Regulatory documentation highlights certain reactions as Serious Adverse Reactions, which, while rare, are clinically significant. These include the potential for Major Hemorrhage (such as severe gastrointestinal or intracranial bleeding). Additionally, the official label includes strong warnings regarding Reye's Syndrome, a rare but severe condition, which restricts use in children and adolescents, particularly those recovering from viral infections.

Population-specific safety constraints are officially defined for several groups. Regulatory sources note an increased risk of gastrointestinal bleeding in older adults. Furthermore, the medicine is contraindicated or strictly restricted in patients with severe hepatic or renal impairment and in those with active peptic ulcer disease or known hemorrhagic diathesis. Tinnitus and hearing impairment are officially listed as potential signs of overexposure.

Overdose and Emergency Response

Overdose and when to seek help

Overdose scope

Feature	Description Based on Official Regulatory Documents
Documented overdose presentations	Initial manifestations of salicylate toxicity often include sensory disturbances like tinnitus and deafness, accompanied by nausea, vomiting, and systemic signs such as sweating and hyperventilation.
Physiological systems affected	Affected systems include the CNS (confusion, agitation, coma, seizures), Respiratory (respiratory arrest, pulmonary oedema), Cardiovascular (hypotension, collapse), and Metabolic/Renal (acidosis, renal failure).
Dose-related or exposure-related factors	Toxicity is classified by severity (mild, moderate, severe) and exposure type (acute vs. chronic intoxication). Chronic toxicity can be more serious and may present with non-specific symptoms.
Population-specific overdose notes	A mandated warning exists for children and teenagers with flu-like symptoms due to the risk of Reye's syndrome. Metabolic acidosis is often the primary acid-base derangement observed in younger children.
Emergency-response statements	Treatment procedures include administration of activated charcoal, use of urinary alkalinisation with sodium bicarbonate, and considering haemodialysis for severe cases. No specific antidote is known for this poisoning.
When immediate medical help is required	Users must seek immediate medical help right away if signs of severe allergic reaction or internal bleeding (e.g., bloody or tarry stools, vomiting blood) are present. Hospital evaluation is required for symptomatic cases.

Overdose classifications (high-level)

Classification Aspect	Regulatory Description or Wording
Severity classification	Classified based on the progression from early symptoms (salicylism) to severe outcomes (e.g., coma, respiratory arrest).
Regulatory basis	Based on the official prescribing information and government-authorized drug monographs.
Overdose-context constraints	Clinical presentation is influenced by age and exposure type, with toxicity sometimes delayed, especially with enteric-coated tablets.

Resulting overdose structure

Official overdose statements:

Tinnitus and hyperventilation are explicitly documented as early clinical signs of toxicity.
Life-threatening outcomes include cerebral oedema and cardiovascular collapse.
Immediate medical help is required for signs of severe allergic reaction or internal bleeding, as mandated by regulatory authorities.
Haemodialysis is an established measure for severe toxicity when warranted by clinical status or laboratory findings.
No specific antidote is known for this intoxication.

Connection to the overall overdose profile: Regulatory documents structure the profile by defining salicylism manifestations and progression to severe outcomes. This informs mandated emergency instructions, which specify precisely when users must seek urgent care, and outlines the required institutional management procedures for the officially recognized toxicity.

Therapeutic Uses of Acard

What Acard Treats: Main Uses and Benefits

The primary therapeutic domain of Acard, which contains acetylsalicylic acid (ASA), is twofold: applied across domains where additional symptomatic support is needed in the context of cardiovascular health and as an anti-inflammatory agent for general relief.

In the context of long-term supportive care, Acard's main use is for the supportive management of recurrent cardiovascular or cerebrovascular symptoms. It is relevant when supportive symptom management is appropriate for patients who have previously experienced conditions marked by increased physiological stress or episodic manifestations. It may assist with easing the overall symptomatic burden associated with these conditions.

ASA is commonly used to help with the supportive management of symptoms linked to organ-specific functional stress. This application assists with maintaining functional stability for individuals dealing with conditions characterized by periods of heightened symptoms.

Additionally, ASA may assist with the supportive management of symptoms related to inflammatory or irritative states and physical discomfort. This supports general well-being during symptomatic phases.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

Aspirin: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Acard?

Acard (Acetylsalicylic acid/ASA) eligibility is defined by official regulatory documents through absolute prohibitions and conditional restrictions. This section outlines the populations permitted and excluded from using the medicine, based strictly on government-approved labeling.

Contraindications: Who Must Not Use Acard

Use is absolutely contraindicated in patients with a known hypersensitivity to ASA or other NSAIDs, active bleeding disorders (e.g., haemophilia or active gastrointestinal haemorrhage), and active peptic ulceration. It is also prohibited for those with severe hepatic impairment, severe renal impairment, or severe heart failure. Additionally, Acard is contraindicated in the third trimester of pregnancy.

Age- and Condition-Based Restrictions

Population Group	Regulatory Status
Children/Adolescents (<16)	Not Recommended due to the risk of Reye's Syndrome in viral illness.
Adults (16+)	Approved for use under standard labeled conditions.
Older Adults	Approved, but use requires caution due to increased risk of gastrointestinal adverse events.

Use requires caution in patients with mild to moderate renal or hepatic impairment, uncontrolled hypertension, and Gout. Furthermore, use during breastfeeding is not recommended by official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes documented drug-drug and drug-product interactions for Acard (Acetylsalicylic Acid/ASA) based on regulatory information.

Clinically Significant Interactions

Interaction Type	Interacting Substance/Class	Constraint/Implication
Absolute Restriction	Methotrexate (ge 15 mg/week)	Contraindicated due to increased hematologic toxicity.
Hemorrhagic Risk	Anticoagulants (e.g., Warfarin), Antiplatelet Agents, SSRIs/SNRIs	Increased risk of bleeding due to additive pharmacodynamic effects.
GI Toxicity	Other NSAIDs (e.g., Ibuprofen), Corticosteroids	Increased risk of GI ulceration and hemorrhage.
Drug Level Alteration	Valproic Acid, Phenytoin	Acard displaces these drugs from plasma protein, altering their free (unbound) plasma concentrations.
Pharmacodynamic	ACE Inhibitors, Diuretics	Diminished blood pressure lowering or diuretic efficacy is documented.

Product and Timing Considerations

Alcohol consumption is documented to increase the risk of gastrointestinal bleeding significantly.

Specific administration timing requirements may exist: the official label advises that co-administration with Ibuprofen may necessitate separation in time to maintain Acard's antiplatelet efficacy. Population-specific notes address increased susceptibility to GI toxicity in the elderly and strict restrictions for use in children or teenagers with viral infections (Reye Syndrome risk).

Mechanism of Action

Permanent Inactivation of Platelet COX-1

The core mechanism involves the irreversible covalent inhibition of the Cyclooxygenase-1 ( COX-1) enzyme in circulating blood platelets. This interaction is mediated by the active substance transferring an acetyl group to the enzyme, leading to the irreversible inactivation of its function. The physiological effect is determined by the fact that platelets cannot synthesize new enzyme, which results in the inactivation lasting for the platelet's entire lifespan.

Suppression of Thromboxane A2 Signaling

By irreversibly blocking COX-1, the drug completely halts the synthesis of Thromboxane A2 ( TXA2), a mediator responsible for triggering platelet stickiness and localized vasoconstriction. This targeted suppression removes the primary biochemical signal for platelet aggregation, which results in the physiological state of reduced thrombotic potential. The mechanism's primary effect is to irreversibly modify the platelet's biochemical machinery for aggregation, resulting in circulating platelets that cannot generate the critical TXA2 signal required for recruitment and clumping. This sustained molecular effect translates into a long-term physiological state of reduced capacity for primary hemostasis.

Dosage and Administration Information

How Acard is Used

The administration of Acard, which contains low-dose Acetylsalicylic acid (ASA), follows established guidelines. Its specific formulation as an enteric-coated tablet dictates the method and conditions of intake, making it suitable for continuous, long-term use.

Official Administration Protocol

The approved route of administration for Acard tablets is oral. For the standard continuous regimen, the dose is taken once daily (qDay), with typical maintenance doses ranging from 75 mg to 162.5 mg. The schedule is designed to be ongoing, establishing it as a long-term therapeutic plan.

Usage Constraint	Official Instruction
Tablet Integrity	The enteric-coated tablet must be swallowed whole and must not be crushed, broken, or chewed.
Timing Relative to Meals	It may be taken with or just after food to mitigate the potential for local gastric irritation.
Initial/Acute Use	Higher doses, up to 450 mg, may be used as an initial loading dose in acute situations.

Population-Specific Guidelines

Administration in older adults generally follows the standard adult dosing regimen unless severe renal or hepatic impairment is present. The medication is generally not indicated for use in children and adolescents under 16 years, unless specifically prescribed by a physician for particular clinical conditions. If a once-daily dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose, in which case the missed dose is skipped. Two doses should not be taken together to compensate for the missed administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acard

Acard contains the active ingredient Acetylsalicylic acid (ASA), which has been the subject of long-term research using high-quality study designs. The evidence base is broadly divided into two main areas: research in individuals who have already experienced a major vascular event (secondary prevention) and research in those considered high-risk but who have not yet had an event (primary prevention).

Evidence for Secondary Prevention of Recurrent Events

The evidence base for this medicine's active ingredient is built upon research exploring its use in individuals who have an established condition, such as prior heart attack, stroke, or unstable chest pain. The central aim of these studies was to examine the recurrence rates of these serious events in the populations studied.

Studies derived from numerous large-scale randomized controlled trials (RCTs) and extensive meta-analyses monitored adult populations with conditions like prior Myocardial Infarction or Ischemic Stroke. Research examined outcomes related to the recurrence of serious vascular events, including non-fatal heart attack, non-fatal stroke, and vascular-related death, often over observation periods lasting several years.

In this secondary prevention context, studies described patterns related to the recurrence rates of serious vascular events compared to control groups over the study duration in this high-risk population. The evidence describes group patterns related to recurrence of vascular conditions among patients with established disease.

Evidence for Primary Prevention in High-Risk Individuals

Research has also explored the potential for the medicine to be used in individuals who are considered to be at a higher risk of a vascular event but who have not yet experienced one. This type of research, known as primary prevention, involves large trials comparing the medicine to a placebo.

Studies monitored two key outcomes: the rate of a first-time Major Adverse Cardiovascular Event (MACE) and, concurrently, the rate of a major bleeding event. Studies monitored measurements related to patterns of difference in the observed rate of first-time vascular events in specific high-risk subgroups. However, studies also consistently reported measurements indicating an increased frequency of major bleeding events compared to placebo across most of the studied populations.

Regulatory bodies and scientific guidelines have noted that there is limited information to support the general use of the medicine across all adults without established vascular disease, citing the fine balance between outcomes and bleeding frequency. Furthermore, there is a specific lack of sufficient evidence to support its initiation solely for primary prevention in older adults (aged 60).

Key Studies & References

USPSTF Recommendation Statement: Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication

Frequently Asked Questions (FAQ)

Common questions about Acard (FAQ)

Q: Is Acard the same as other low-dose aspirins?

A: Acard is a specific brand of low-dose Acetylsalicylic acid (ASA), formulated as an enteric-coated tablet. While all low-dose aspirins contain the same active ingredient, different preparations may vary in dose strength or formulation, which can affect how the medicine is absorbed in the body.

Q: What is the difference between Acard and standard aspirin?

A: Acard is primarily a low-dose formulation intended to inhibit platelet aggregation for circulatory purposes. Standard aspirin, which contains a higher amount of the active ingredient (ASA), is typically used for the temporary relief of pain or fever. Regulatory documents categorize them differently based on their primary intended use.

Q: How quickly does Acard start working in the body?

A: The active ingredient in Acard irreversibly modifies platelets to inhibit their stickiness, and this effect lasts for the entire lifespan of the platelet, about 7 to 10 days. Official product information notes that enteric-coated formulations, like Acard, are designed for delayed release, meaning they have a slower initial onset of action compared to non-coated tablets.

Q: Do you need a prescription to buy Acard?

A: The active ingredient in Acard, low-dose ASA, is often available to purchase without a prescription (over the counter) in many jurisdictions. However, it may also be prescribed by a physician, depending on the dose and the specific health condition being managed.

Q: Is Acard only for people who have already had a heart event?

A: No. Regulatory documents confirm the use of the medicine's active ingredient in people who have had a prior event (secondary prevention). It is also used in certain high-risk individuals who have not yet had an event (primary prevention), although this use is generally subject to specific medical guidelines.

Q: Is it safe to take supplements like fish oil with Acard?

A: Regulatory information indicates that some supplements, such as fish oil (omega-3 fatty acids), may rarely increase the risk of bleeding when combined with antiplatelet medicines. Patients are generally advised to inform their healthcare provider about all supplements used to understand potential interactions.

Q: Is Acard used for pain relief as well as for its main purpose?

A: Acard is classified as an antiplatelet agent and is formulated in a low dose specifically for circulatory purposes. While the active ingredient (ASA) is also found in higher doses used for pain relief, the primary function of Acard is to inhibit platelet aggregation.

Q: Why are there different doses of Acard available?

A: The active ingredient (ASA) is available in different strengths because various doses are indicated for different purposes, according to regulatory guidelines. These different doses are used for clinical goals ranging from an initial acute loading dose to a long-term maintenance regimen.

Q: What is the typical duration of treatment with Acard?

A: For its purpose in preventing recurrent vascular events (secondary prevention), treatment with the active ingredient is generally described in official documents as intended to be continuous and long-term.

Q: Does Acard make you feel dizzy or sleepy?

A: Officially documented common adverse effects for low-dose ASA focus primarily on gastrointestinal and bleeding issues. Tinnitus (ringing in the ears) is officially listed as a potential symptom of overexposure to the active ingredient.

Q: What should I do if I notice blood in my stool while on Acard?

A: Regulatory safety information warns that dark, bloody, or tarry stools are signs of potential gastrointestinal bleeding, which is listed as a Serious Adverse Reaction. Official safety information notes that in the event these symptoms occur, it is important to seek immediate attention from a healthcare provider.

Q: Can I stop taking Acard suddenly?

A: Regulatory guidance for antiplatelet therapy consistently suggests that the decision to discontinue must only be made by a healthcare provider. This is especially important for patients taking the medicine for cardiovascular event prevention.

Q: Why do some people take Acard before surgery?

A: The active ingredient affects bleeding time. Its use before a surgical procedure is part of a clinical assessment by the physician to balance the risk of bleeding during the surgery against the risk of a blood clot forming if the medicine is stopped.

Q: Is there a best time of day to take Acard?

A: Official administration protocols state that the medicine is taken once daily. It is typically advised to take the dose with or immediately after food to help reduce the potential for gastric irritation, but no specific optimal time of day is mandated in regulatory documents.

Q: Are there any known long-term risks of taking Acard?

A: Yes, long-term risks officially documented in regulatory information include the potential for gastrointestinal ulceration and hemorrhage (bleeding), particularly in the stomach or gut.

Q: Does Acard affect dental procedures?

A: Because taking Acard affects bleeding time, in line with medical guidance, consulting with a physician and dentist before any dental procedure is generally recommended.

Q: What regulatory bodies have approved Acard for use?

A: The active ingredient in Acard, Acetylsalicylic acid (ASA), is approved by numerous global regulatory bodies for its antiplatelet function. These include agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Q: Does Acard have drug interactions with herbal remedies?

A: Regulatory documents mention the importance of informing a healthcare provider about all medications and herbal products used, as some herbal products may interact with antiplatelet medicines and potentially increase the risk of bleeding.

Q: Is Acard used to treat stroke or to prevent it?

A: Official documents indicate that the medicine is used for both the prevention of recurrent vascular events, such as stroke and heart attack, and for its use as a component of treatment in acute situations like a recent heart attack or ischemic stroke.

Q: Can Acard be taken if I have asthma?

A: Use of the active ingredient (ASA) is contraindicated in individuals who have experienced an allergic-type reaction, such as worsening asthma symptoms, after taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).

Q: How is Acard different from an anticoagulant?

A: Acard is classified as a platelet aggregation inhibitor (antiplatelet agent) because it prevents platelets from clumping together. Regulatory documents list Acard as having a significant interaction with anticoagulants (which affect clotting factors), as taking both together increases the risk of bleeding due to additive effects.

Q: Can Acard be taken with paracetamol (acetaminophen)?

A: Regulatory-derived drug interaction checkers typically show no pharmacological interaction between the active ingredient in Acard and paracetamol (acetaminophen).

Q: Is Acard a generic or a brand-name medicine?

A: Acard is a specific brand name for a medicine containing the active ingredient Acetylsalicylic acid (ASA). The generic component, ASA, is available under various names and formulations globally.

Q: Does Acard expire quickly?

A: Official storage documents state that the product must be stored at a Controlled Room Temperature, protected from moisture, and must not be used past the labeled expiration date printed on the package.

Q: Why is Acard prescribed for heart problems?

A: The active ingredient is prescribed to help prevent serious vascular events. This includes preventing recurrent heart attack, stroke, or unstable chest pain in high-risk individuals or those who have already experienced such events.

Q: What are the most common reasons doctors suggest Acard?

A: The most common reasons relate to the prevention of recurrent serious vascular events such as heart attack and ischemic stroke, in individuals with established cardiovascular disease, as described in regulatory indications.

Q: Are there any age limits for taking Acard?

A: Yes. Acard is generally not recommended for children and adolescents under 16 years. For older adults (aged 60 and above), regulatory guidelines note limited information to support its general use for primary prevention.

Q: Can Acard cause stomach problems?

A: Yes. Officially documented common adverse reactions include effects in the gastrointestinal system, such as dyspepsia (indigestion) and increased tendencies toward minor bleeding.

Q: Is it normal to have mild bruising while taking Acard?

A: The drug's mechanism is designed to reduce platelet stickiness, and regulatory documents list increased tendencies toward minor bleeding, such as bruising, as a common, officially documented effect.

Q: Does Acard interact with ibuprofen or NSAIDs?

A: Yes. Taking Acard with other NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), such as ibuprofen, is documented to increase the risk of gastrointestinal irritation and hemorrhage. Official instructions may advise separating the timing of the doses.

Q: Are there foods or drinks that should be avoided when using Acard?

A: Regulatory documents advise against consuming alcohol while taking the medicine, as it can significantly increase the risk of gastrointestinal bleeding. No general food groups are advised to be strictly avoided.

Q: Can pregnant women or those planning pregnancy use Acard?

A: Regulatory guidance states that the medicine is contraindicated in the last three months of pregnancy. Use during the first six months or when planning pregnancy should only occur if absolutely necessary and under strict medical advice.

Q: Why do instructions say to take Acard with food?

A: Administration instructions advise taking the medicine with or immediately after food. This is done to help mitigate the potential for local irritation to the stomach lining, a common issue associated with the active ingredient.

How should Acard be stored and disposed of?

Acard must be stored under specific conditions to maintain the stability of acetylsalicylic acid. The medication must be kept at a Controlled Room Temperature, typically between 15^circC and 30^circC (59^circF and 86^circF).

Requirement	Specification	Constraint
Temperature	Controlled Room Temp.	Do not exceed 30^circC
Environment	Must be stored in a dry place	Protect from moisture and high humidity
Container	Keep the container tightly closed	Do not use past the labeled expiration date
Safety	Keep out of the reach of children	Mandatory child-protection rule

Disposal must follow official guidelines to protect the environment. Unused or expired tablets should be disposed of in accordance with local regulations or at an approved waste disposal plant. The product should not be allowed to enter drains or water sources.

Acard